300439.SHE Ningbo MedicalSystem Biotechnology Co Ltd
- Market cap
- CNY 3.83B
- P/E
- 35.6x
- P/B
- 1.20x
- ROE
- 4.3%
- Dividend yield
- 1.36%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300439.SHE undervalued?
Graham number300439.SHE trades 37.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ningbo MedicalSystem Biotechnology Co Ltd fundamental analysis
No fundamental analysis for Ningbo MedicalSystem Biotechnology Co Ltd yet.
Ningbo MedicalSystem Biotechnology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. researches, develops, produces, and sells in vitro diagnostic products in China. It is also involved in the provision of third-party medical diagnostic services. The company offers chemiluminescence, biochemistry, integrated combination, TLA system, hematology, point-of-care testing (POCT), mass spectrometry, and blood lipid subfraction analysis. It also provides healthcare services. Medicalsystem Biotechnology Co., Ltd. was formerly kno…
Full company profileNingbo MedicalSystem Biotechnology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ningbo MedicalSystem Biotechnology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.06B | 2.58B | 3.14B | 3.13B | 2.30B | 2.25B | 2.49B | 1.89B | 1.74B | 1.54B | 1.70B |
| Gross Profit | 566M | 968M | 1.07B | 1.03B | 830M | 904M | 937M | 825M | 770M | 566M | 625M |
| Operating Income | 210M | 346M | 342M | -525M | 173M | 220M | 229M | 279M | 268M | 61.4M | 143M |
| EBITDA | 306M | 489M | 575M | -282M | 576M | 422M | 409M | 459M | 475M | 221M | 147M |
| Net Income | 177M | 230M | 241M | -560M | 299M | 179M | 199M | 257M | 258M | 63.2M | 130M |
| EPS | 0.52 | 0.66 | 0.70 | -1.63 | 0.87 | 0.48 | 0.52 | 0.67 | 0.67 | 0.16 | 0.34 |
| Balance Sheet | |||||||||||
| Total Assets | 3.42B | 4.28B | 4.60B | 3.74B | 3.25B | 3.59B | 3.58B | 3.49B | 3.71B | 3.65B | 3.72B |
| Total Liabilities | 1.59B | 1.99B | 2.33B | 2.35B | 1.57B | 1.20B | 1.06B | 782M | 772M | 706M | 687M |
| Shareholders' Equity | 1.62B | 1.89B | 1.87B | 1.34B | 1.64B | 2.35B | 2.51B | 2.71B | 2.94B | 2.95B | 3.04B |
| Cash & Short-term Investments | 315M | 379M | 417M | 437M | 328M | 767M | 887M | 965M | 890M | 658M | 388M |
| Total Debt | 464M | 1.20B | 1.57B | 1.50B | 927M | 482M | 332M | 73.6M | 67.1M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.45M | -128M | 419M | 601M | 912M | 515M | 565M | 634M | 398M | 267M | - |
| Capital Expenditure | 293M | 412M | 446M | 363M | 383M | 202M | 303M | 280M | 421M | 191M | 50.2M |
| Free Cash Flow | -290M | -541M | -27.4M | 238M | 529M | 314M | 262M | 353M | -22.7M | 75.2M | 16.9M |
| Ratios | |||||||||||
| ROE | 11.0% | 12.1% | 12.9% | -41.9% | 18.2% | 7.6% | 7.9% | 9.4% | 8.8% | 2.1% | 4.3% |
| ROA | 5.2% | 5.4% | 5.2% | -15.0% | 9.2% | 5.0% | 5.5% | 7.4% | 7.0% | 1.7% | 3.5% |
| Net Profit Margin | 16.8% | 8.9% | 7.7% | -17.9% | 13.0% | 8.0% | 8.0% | 13.6% | 14.8% | 4.1% | 7.7% |
| Debt to Equity | 0.29x | 0.63x | 0.84x | 1.12x | 0.56x | 0.21x | 0.13x | 0.03x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ningbo MedicalSystem Biotechnology Co Ltd dividends
- Dividend yield
- 1.36%
- Forward dividend
- 0.03 CNY
- Payout ratio
- 82.3%
- Ex-dividend date
- Jun 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 52.0M | 0.14 | 82.3% |
| 2024 | CNY 52.5M | 0.14 | 20.3% |
| 2023 | CNY 49.9M | 0.13 | 19.4% |
| 2022 | CNY 36.4M | 0.10 | 18.3% |
| 2021 | CNY 60.0M | 0.16 | 33.4% |
| 2020 | CNY 125M | 0.36 | 41.9% |
| 2019 | CNY 50.2M | 0.15 | - |
| 2018 | CNY 116M | 0.34 | 48.3% |
| 2017 | CNY 49.2M | 0.14 | 21.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 30:10 on Sep 17, 2015.
Who owns Ningbo MedicalSystem Biotechnology Co Ltd
- Insiders 49.15%
- Institutions 0.70%
- Public & others 50.15%
- Shares outstanding 384M
- Free float 202M
Ningbo MedicalSystem Biotechnology Co Ltd company profile
- Company name
- Ningbo MedicalSystem Biotechnology Co Ltd
- Ticker
- 300439.SHE
- ISIN
- CNE100001Z25
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,936
- Fiscal year end
- December
- Address
- No. 1228, Jinda South Road, Ningbo, China, 315104
- Phone
- 86 57 4553 37009
- Website
- nbmksw.com
About Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. researches, develops, produces, and sells in vitro diagnostic products in China. It is also involved in the provision of third-party medical diagnostic services. The company offers chemiluminescence, biochemistry, integrated combination, TLA system, hematology, point-of-care testing (POCT), mass spectrometry, and blood lipid subfraction analysis. It also provides healthcare services. Medicalsystem Biotechnology Co., Ltd. was formerly known as Ningbo Medicalsystem Biotechnology Co., Ltd. and changed its name to Biotechnology Co., Ltd. in January 2017. The company was founded in 2003 and is based in Ningbo, China.
Ningbo MedicalSystem Biotechnology Co Ltd management
5- Mr. Ji Hua ZouGM & Non-Independent Director · born 1979
- Ms. Huiping XiongDeputy GM, CFO & Board Secretary · born 1979
- Mr. Min ShenDeputy General Manager · born 1981
- Mr. Liang FangDeputy General Manager · born 1980
- Ting WangHead of Accounting Department